Clinical Trial Detail

NCT ID NCT02350764
Title Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Age Groups: adult

Additional content available in CKB BOOST